AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million

Core Viewpoint - AIM ImmunoTech Inc. has announced preliminary results of its rights offering, estimating total subscriptions of approximately $1.8 million, aimed at funding the development of its lead product, Ampligen® for late-stage pancreatic cancer treatment [1][3]. Group 1: Rights Offering Details - The rights offering allowed holders to purchase one unit at a subscription price of $1,000, which included one share of Series G Convertible Preferred Stock and 2,000 Class G Common Stock Purchase Warrants [2]. - The closing of the rights offering is anticipated to occur on or about March 6, 2026, pending the satisfaction of all closing conditions [3]. Group 2: Company Overview - AIM ImmunoTech Inc. is focused on the research and development of Ampligen® (rintatolimod), an immuno-modulator that has shown broad-spectrum activity in clinical trials for treating late-stage pancreatic cancer, a significant global health issue [7].